eIF-5A2 siRNA

**eIF-5A2 siRNA** is a small interfering RNA designed to selectively silence the expression of the gene encoding eukaryotic translation initiation factor 5A2 (EIF5A2). EIF5A2 is an oncogene highly expressed in various cancers, including hepatocellular carcinoma (HCC), gastric cancer, and non-small cell lung cancer (NSCLC)[1][3][5]. Targeted knockdown of EIF5A2 by siRNA inhibits tumor cell proliferation, migration, invasion, and enhances sensitivity to chemotherapeutic agents like doxorubicin and cisplatin by inducing autophagic cell death[2][3][5]. The mechanism of action is post-transcriptional gene silencing via RNA interference, specifically reducing EIF5A2 mRNA and protein levels, which in turn disrupts tumor-promoting processes such as cell cycle progression, epithelial-mesenchymal transition (EMT), and metastasis[3][4]. Therapeutically, eIF-5A2 siRNA is studied as a gene therapy modality for both standalone and combination regimens to overcome chemoresistance[3][5]. Development has largely focused on preclinical and early clinical models.

Other names

EIF5A2-specific siRNAEIF-5A2-specific siRNAEIF 5A2-specific siRNAEIF5A2 silencing RNAEIF-5A2 silencing RNAEIF 5A2 silencing RNAsiEIF5A2siEIF-5A2siEIF 5A2